{"id":"W4399960956","doi":"10.1530/erc-23-0337","title":"Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study","year":2024,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Ipsen; Sanofi; Exelixis; Advanced Accelerator Applications; Gilead Sciences; Eisai; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lanreotide; Medicine; Clinical endpoint; Placebo; Internal medicine; Gastroenterology; Neuroendocrine tumors; Phases of clinical research; Surgery; Randomized controlled trial; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001142367,0.001114282,0.00243587,0.0003162267,0.0002718494,0.0008658956,0.0006673832,0.001162152,0.003828935],"category_scores_gemma":[0.0006860201,0.0003925072,0.001617365,0.000280979,0.0006781113,0.0007199363,0.0002625904,0.002132002,0.0008518074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005091747,"about_ca_system_score_gemma":0.001066597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006688314,"about_ca_topic_score_gemma":0.001932075,"domain_scores_codex":[0.9997064,0.0001541262,0.00001453696,0.00004353122,0.00003900715,0.00004240772],"domain_scores_gemma":[0.9995265,0.00009085389,0.00010347,0.00003129686,0.000040158,0.0002078413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9054965,0.02596558,0.0008593384,0.001197782,0.001328658,0.00008454462,0.0000776306,0.0005361866,0.01502925,0.000144954,0.001296905,0.04798263],"study_design_scores_gemma":[0.7482173,0.2463045,0.002362171,0.00004569473,0.0004945937,0.00007287139,0.00002787047,0.0003863778,0.0008803398,0.0001298003,0.001063432,0.00001511092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850109,0.008306773,0.0006473311,0.0005396487,0.0004265633,0.002012397,0.0009467504,0.0001178401,0.001991738],"genre_scores_gemma":[0.9797993,0.007577893,0.001974157,0.001627226,0.000560812,0.003096746,0.00158684,0.00003893189,0.003738112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003828935,"threshold_uncertainty_score":0.0128091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01840343130983612,"score_gpt":0.3733725241638662,"score_spread":0.3549690928540301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}